We examined the involvement of sphingosine kinase-1, a critical regulator of the sphingolipid balance, in susceptibility to antineoplastic agents of either sensitive or multidrugresistant acute myeloid leukemia cells. Contrary to parental HL-60 cells, doxorubicin and etoposide failed to trigger apoptosis in chemoresistant HL-60/Doxo and HL-60/VP16 cells overexpressing MRP1 and MDR1, respectively. Chemosensitive HL-60 cells displayed sphingosine kinase-1 inhibition coupled with ceramide generation. In contrast, chemoresistant HL-60/ Doxo and HL-60/VP16 had sustained sphingosine kinase-1 activity and did not produce ceramide during treatment. Enforced expression of sphingosine kinase-1 in chemosensitive HL-60 cells resulted in marked inhibition of apoptosis that was mediated by blockade of mitochondrial cytochrome c efflux hence suggesting a control of apoptosis at the premitochondrial level. Incubation with cell-permeable ceramide of chemoresistant cells led to a sphingosine kinase-1 inhibition and apoptosis both prevented by sphingosine kinase-1 overexpression. Furthermore, F-12509a, a new sphingosine kinase inhibitor, led to ceramide accumulation, decrease in sphingosine 1-phosphate content and caused apoptosis equally in chemosensitive and chemoresistant cell lines that is inhibited by adding sphingosine 1-phosphate or overexpressing sphingosine kinase-1. F-12509a induced classical apoptosis hallmarks namely nuclear fragmentation, caspase-3 cleavage as well as downregulation of antiapoptotic XIAP, and release of cytochrome c and SMAC/Diablo. Leukemia (2006) 20, 95-102.
Introduction
Sphingolipid metabolites, ceramide and sphingosine 1-phosphate (S1P) have garnered considerable attention over the last decade as critical mediators of cell death or survival. Ceramide, the central molecule in sphingolipid metabolism, mediates apoptosis in response to a wide array of anticancer treatments. Chemotherapy and radiotherapy elicit an increase in endogenous ceramide level occurring prior to the first biochemical signs of apoptosis, namely mitochondrial release of apoptogenic proteins and activation of effector caspases (reviewed in Ogretmen and Hannun 1 ). Moreover, addition of exogenous short-chain ceramides causes apoptosis in numerous cancer cell lines (reviewed in Ogretmen and Hannun 1 ).Contrary to ceramide, S1P promotes cell survival in response to apoptotic stresses that induce ceramide generation in vitro, ex vivo and in vivo.
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Thus a 'sphingolipid rheostat' has been hypothesized where the dynamic balance between ceramide versus S1P, and consequent regulation of opposing signaling pathways, may be an important factor determining survival or death of mammalian cells. 2 A crucial regulator of this ceramide/S1P balance is sphingosine kinase-1 (SphK1) -an enzyme that phosphorylates sphingosine (the catabolite of ceramide) to form S1P -because it reduces proapoptotic ceramide levels by driving sphingolipid metabolism toward the antiapoptotic S1P (reviewed in Cuvillier 5 , Spiegel and Milstien 6 ). Enforced expression of SphK1 results in inhibition of apoptosis induced by stress agents that increase ceramide levels. [7] [8] [9] [10] On the other hand, inhibition of SphK activity by N,N-dimethylsphingosine, a sphingosine derivative, elicits apoptosis that can be blocked by addition of exogenous S1P. 2, 11, 12 Dysregulation of this two-pan balance may be critical in the acquisition of malignant phenotype in which transformed cells outwit apoptotic mechanisms that initiate destruction of mutated cells. As a matter of fact, in line with classical models of cell transformation, Vadas and coworkers found that fibroblasts overexpressing SphK1 acquire the transformed phenotype in tissue culture and capability to develop tumors in nude mice. 13 Additionally, mRNA amount for SphK1 has been found significantly higher in tumor cells than in healthy cells.
14 Also, consistent with the idea that ceramide is a mediator of apoptosis, lack of generation of ceramide has been linked to tumor-cell resistance. Radiation-resistant and chemoresistant cell lines do not generate ceramide after irradiation or chemotherapy, [15] [16] [17] [18] [19] a defect that could be bypassed by addition of cell-permeable ceramides. Interestingly, a correlation has even been established between SphK1 activity and resistance to irradiation in prostate cancer cells. We have indeed shown that SphK1 activity was not affected by ionizing radiations in radioresistant LNCaP cells, whereas SphK1 was markedly inhibited in radiosensitive TSU cells. 18 These results suggest that SphK1 inhibition is associated with radiationinduced apoptosis in sensitive cells in order to halt production of S1P, the antiapoptotic sphingolipid.
To further substantiate a role for SphK1 as an indicator of sensitivity or resistance in tumor cells, we have now examined its involvement in susceptibility to antineoplastic agents in sensitive and drug-resistant HL-60 acute myeloid leukemia (AML) cells. The development of refractory disease in AML is frequently correlated with the expression of one or several multidrug resistance (MDR) genes, such as MDR1 or MRP1 (reviewed in Sonneveld 20 ). In this study, we found that SphK1 activity was downregulated in HL-60 cells sensitive to doxor-ubicin or etoposide contrary to MDR1-or MRP1-positive HL-60 cells. Enforced expression of SphK1 in sensitive HL-60 cells could block apoptosis whereas a specific pharmacological inhibition of sphingosine kinase activity by the new compound F-12509a could overcome chemoresistance by inducing a mitochondria-dependent apoptosis. Overall this study strongly suggests that SphK1 is a good target for efficiently circumventing the chemoresistance problem in AML, by the use of sphingosine kinase inhibitors that can simultaneously cause both ceramide production and S1P depletion.
Experimental procedures

Cell lines
HL-60 cells were cultured in RPMI1640 containing 15% FBS as previously described.
11 HL-60/Doxo resistant cells (gift of Dr JP Marie, Hô tel Dieu, Paris, France) were grown in the same medium supplemented with 40 nM doxorubicin. 21, 22 The selection of HL-60/VP16 cells was performed by stepwise increasing concentrations of etoposide, and cells were maintained continuously in the presence of 1 mM VP16. FLAG epitope-tagged wild-type human SphK1 (hSphK1) cDNA and hSphK1 containing the Gly 82 -Asp mutation, subcloned into pcDNA3* vector, 23 were used for stable transfection in HL-60 cells. Mass pools of stable tranfectants were selected in growth medium containing 2 mg/ml G418. Empty vector-, wild-type hSphK1-and hSphK1
G82D -transfected HL-60 cells were designated HL-60/neo, HL-60/SphK1, and HL-60/SphK1-DN, respectively. All experiments were conducted in the presence of 15% serum at an initial concentration of 1.10 6 cells/ml, and then treated as indicated in the figures.
Materials
Culture medium, serum and antibiotics were obtained from Invitrogen. Doxorubicin and etoposide (VP16) were from Teva Pharma (Courbevoie, France) and Sigma-Aldrich, respectively. D-erythro-N-acetylsphingosine (C 2 -Ceramide, Sigma-Aldrich) and S1P (Avanti-Polar Lipids, Alabaster, AL) were delivered as a complex with bovine serum albumin (BSA) in 4 mg/ml BSA (fatty-acid free, Sigma-Aldrich). The phorbol ester tetradecanoylphorbol-13-acetate (TPA) was from Sigma-Aldrich. Escherichia coli strain expressing diacylglycerol kinase was a gift of Dr Y Hannun (Medical University of South Carolina, Charleston, SC). Stock solutions (20 mM) of the sesquiterpene quinone F-12509a were prepared in DMSO and stored at À201C. A 1 mM solution DMSO/RPMI1640 (1:4, v/v) was prepared for the experiments. (g-32 P)ATP (3000 Ci/mmol) was purchased from Perkin-Elmer, and silica gel high-performance TLC (Partisil s LK6D) plates were from Whatman International.
Cell viability and staining of apoptotic nuclei
Cell viability was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) dye reduction assay as previously described. 2 Apoptosis was assessed by staining cells with 8 mg/ml 4 0 ,6-diamidino-2-phenylindole (DAPI, SigmaAldrich) for 10 min. Cells were then examined with a Leica fluorescent microscope. Apoptotic cells were distinguished by condensed, fragmented nuclear regions. 24 
RNA interference experiments
Transient interference was efficiently achieved by doublestranded SphK1-specific siRNA 5 0 -GGG CAA GGC CUU GCA 
Western blot analysis and antibodies
Total and mitochondria-free cell lysate preparation and Western blotting were carried out as previously reported. Sphingosine kinase-1 assay and Mass measurements of ceramide, sphingosine 1-phosphate and phospholipids SphK1 activity was performed as described previously 25 under conditions for which SphK1 activity is optimal, 26 and determined in the presence of 50 mM sphingosine, 0.25% Triton X-100 and [g-32 P]ATP (10 mCi, 1 mM) containing 10 mM MgCl 2 . The labelled S1P was separated by thin layer chromatography on silica gel 60 with 1-butanol/ethanol/acetic acid/water (80:20:10:10, v/v) and visualized by autoradiography. Activity was expressed as picomoles of S1P formed/min/mg of protein.
Amounts of ceramide were measured by the E. coli enzyme diacylglycerol kinase. 27 [ 32 P]ceramide 1-phosphate was extracted, resolved from other reaction products by TLC using chloroform/acetone/methanol/acetic acid/water (50:20:15:10:5, v/v) as developing solvent, and quantitated by liquid scintillation counting. Intracellular S1P content was measured as described by Edsall et al. 28 Briefly, to aqueous phase of Folch extraction buffer C (200 mM Tris-HCl, pH 7.4, 75 mM MgCl 2 in 2 M Glycine, pH 9.0) was added (1:6, v/v) and S1P was dephosphorylated by addition of 50 U/sample of alkaline phosphatase for 30 min, 371C. Reaction was stopped by addition of HCl and organic phase containing sphingosine separated and evaporated. Evaporated sphingosine was resuspended in 'SphK' buffer with 0.25% Triton X-100. Sphingosine was converted to S1P by addition of cytosolic extracts of SphK1-overexpressing PC-3 cells and [g- Total phospholipids present in cellular lipid extracts used for sphingolipid analysis were quantified as follows. To dried aliquots of cellular lipid extracts, 70 ml of 70% perchloric acid was added, and samples were heated at 1801C for 2 h in a sand bath. After cooling, 1 ml of buffer A (0.22% ammonium molybdate in 2% (v/v) concentrated H 2 SO 4 ) and 40 ml of buffer B (15% NaHSO 4 , 0.5% Na 2 SO 3 , 0.25% 1-amino-2-hydroxy-4-naphthalenesulphonic acid) were added. Samples were left at 1001C for 15 min, and absorbance measured at 810 nm.
Flow cytometry analysis
IntraPrep, the isotypes IgG1, IgG2a, primary monoclonal antibody UIC2 and goat F(ab 0 ) fragment mouse IgG (H þ L)-FITC were obtained from Immunotech (Marseille, France). The primary monoclonal antibody MRPm6 was obtained from Alexis (San Diego, CA). For Pgp expression, fixed cells were washed and incubated for 45 min at room temperature in presence of 20 ml of 5 ml/ml of either UIC2 antibody that recognizes an external epitope of the Pgp or IgG2a isotype for control. Cells were washed with ice cold PBS containing 1% BSA, 5% fetal calf serum and incubated for 15 min at room temperature and in the dark in presence of F(ab 0 )2 fragment of goat anti-mouse IgG-FITC diluted to 1:50. For MRP1 expression, the monoclonal antibody MRPm6 (2.5 mg/ml) was used as described earlier. 
Statistical analysis
Statistical analysis was performed using the unpaired Student's t-test (GraphPad s Instat 3 program).
Results
Doxorubicin and etoposide failed to induce apoptosis in chemo-resistant HL-60 cells in contrast to parental cells
The degree of resistance to doxorubicin and etoposide in parental HL-60, HL-60/Doxo and HL-60/VP16 was measured by MTT cell survival assay. As reported previously, 19 ,30 treatment of parental HL-60 cells with 1 mM doxorubicin or 5 mM etoposide led to a severe loss of cell viability (Figure 1a ). Cellular viability loss was characteristic of apoptosis with appearance of the classical hallmarks, namely nuclear fragmentation (data not shown), release of mitochondrial cytochrome c and activation of executioner caspase-3 and -7, accompanied by proteolytic processing of PARP (Figure 1d ). In contrast to the chemosensitive parental HL-60, HL-60/Doxo (Figure 1b) and HL-60/VP16 (Figure 1c ) cell lines demonstrated full resistance to both doxorubicin (1 mM) and etoposide (5 mM) with respect to apoptosis induction up to 72 h of treatment. As a result, there was no detectable cytochrome c accumulation, no processing of executioner caspase-3 and -7, nor PARP cleavage in these chemoresistant cell lines (Figure 1d ). Chemoresistance is commonly associated with overexpression of MDR1 and MRP1 genes in cells that are resistant to anthracyclines, vinca alkaloids, or other agents. Hence, we sought to determine the contribution of MDR1 and/or MRP1 genes in the resistance of HL-60/Doxo and HL-60/VP16 cells. Using MRPm6 and UIC2 antibodies that recognize MDR1 and MRP1 proteins respectively, flow cytometry analysis showed overexpression of MRP1 (ratio value ¼ 3.75) but not MDR1 in HL-60/Doxo; 31 while HL-60/VP16 cells overexpress MDR1 (ratio value ¼ 4.50), but not MRP1 (data not shown).
Doxorubicin-or etoposide-induced apoptosis is associated with SphK1 inhibition and ceramide production
Previously we have reported that, in contrast to radioresistant cells, SphK1 activity was downregulated in prostate adenocarcinoma cells sensitive to g-irradiation-induced apoptosis, while ceramide level was upregulated. 18 To examine whether there was a similar correlation between SphK1 activity, ceramide content and the susceptibility of AML cells to chemotherapeutics, these parameters were assessed in our cell systems. Exposure of parental HL-60 cells to doxorubicin or etoposide produced a sharp decrease in SphK1 activity evident as early as 30 min of treatment and peaking at 90-120 min (Figure 2a ). Downregulation of SphK1 activity was sustained for several hours, and then SphK1 activity went back to normal. In correspondence with the SphK1 inhibition, both drugs elicited an acute generation (around 50% increase) of the proapoptotic lipid ceramide peaking after 90-120 min of contact (Figure 2a ). It should be pointed out that elevation of ceramide and SphK1 inhibition preceded the onset of apoptosis as no activation of executioner caspases could be found before at least 12-24 h of treatment (data not shown). Remarkably, differing from the parental cell line, we could not detect any significant changes in both SphK1 activity and ceramide content upon doxorubicin or etoposide (Figure 2a ) treatment in both chemoresistant cells. Therefore, as proposed for g-irradiation of prostate cancer cells, 18 there seems to exist a reverse correlation during chemotherapy between ceramide level and SphK1 activity in chemosensitive acute myeloid leukemia HL-60 cells, that is not observed in chemoresistant variants. 
SphK1 overexpression inhibits apoptosis induced by anticancer drugs
In order to firmly establish a role for SphK1 in the regulation of apoptosis, we generated stable populations of HL-60 cells overexpressing either FLAG epitope-tagged wild-type SphK1 (HL-60/SphK1), or the hSphK1 G82D catalytically inactive form (HL-60/SphK1-DN). Western blot analysis using anti-FLAG antibody revealed a specific protein band in HL-60/SphK1 and HL-60/SphK1-DN cells that was absent in empty vectortranfected HL-60/neo cells ( Figure 2b ). As previously reported in HEK293 cells, 23 transfection with FLAG-tagged SphK1 resulted in a significant higher SphK1 activity (Figure 2c) . In contrast, similar expression of hSphK1 G82D produced no detectable increase in SphK1 activity when compared to empty vector-tranfected cells (Figure 2c ). Even though this mutation did not have any impact on basal SphK1 activity, it did prevent its activation by the phorbol ester TPA (Figure 2d) indicating that the mutated hSphK1 could act as a dominant-negative. 23 Exogenous added S1P has been shown to thwart apoptosis triggered by various stress agents in HL-60 cells. 2, 11, 12 In addition, overexpression of mSphK1 can inhibit doxorubicininduced apoptosis in MCF-7 breast cancer cells. 9 Thus, it was of interest to determine whether increasing intracellular level of S1P by enforced expression of hSphK1 could be effective in preventing HL-60 cell death in response to chemotherapeutics. Stable expression of hSphK1 well inhibited apoptosis induced by both doxorubicin and etoposide (Figure 2e) . Further establishing that SphK1 activity was indeed important in regulation of apoptosis, HL-60 cells overexpressing the dominant-negative form of hSphK1 were even somewhat more prone to die upon treatment with doxorubicin or etoposide (Figure 2e ). Previously, we have shown that exogenous S1P was antagonizing apoptosis in leukemia cells by inhibiting the efflux of mitochondrial cytochrome c. 11 We therefore asked whether overexpression of SphK1 was capable of blocking apoptosis at the mitochondrial level. As shown in Figure 2f Cell-permeable ceramide induces apoptosis in both sensitive and resistant HL-60 cells that can be blocked by hSphK1-enforced expression As we could not detect any increased content of pro-apoptotic ceramide in chemo-resistant cells, we attempted to determine whether bypassing this obstruction by adding exogenously cellpermeable ceramide could restore apoptosis in these cells. We found that increasing endogenous ceramide level by direct addition of short chain ceramide (C 2 -ceramide) could trigger loss of cell viability in HL-60/Doxo (Figure 3a) as well as in HL-60/VP16 cell lines (data not shown). Of interest, under these conditions, SphK1 activity was quickly and strongly downregulated as illustrated in HL-60/Doxo cells (Figure 3b ). This effect was also seen in HL-60/VP16 cells (data not shown). To verify whether C 2 -ceramide had any SphK1 inhibiting properties, we tested its influence on SphK1 activity in test tube, and found no inhibition of SphK1 (data not shown), thus showing that C 2 -ceramide-induced SphK1 inhibition is not direct. As already shown for doxorubicin and etoposide (Figure 2e) , there was significantly less apoptosis in cells overexpressing hSphK1 when challenged by cell-permeable ceramide (Figure 3c ).
SphK1 knockdown by RNA interference induces apoptosis in chemoresistant HL-60 cells
To establish proof-of-concept that SphK1 downregulation was critical for mediating cytotoxic effects of chemotherapeutics, we examined the effects of SphK1 siRNA on cell viability. SiRNA targeted against hSphK1 10, 32 clearly led to loss of cellular The sphingosine kinase inhibitor F-12509a can overcome chemoresistance via the mitochondrial apoptotic pathway
The F-12509a sesquiterpene quinone was isolated from a culture broth of a discomycete, Trichopezizella barbata SANK 25395. 33 F12509a acts as a competitive inhibitor for SphK1 with a K i of approximately 4 mM. 34 As anticipated, under exposure to F-12509a, SphK1 activity was strongly inhibited in chemoresistant HL-60/Doxo cells or HL-60/VP16 (Figure 4e and f) . Concomitant with SphK1 inhibition, a drop in S1P levels was observed (Figure 4e and f) . Interestingly, increase in ceramide content was also concurrently associated with downregulation of SphK1 activity (Figure 4e and f) . As illustrated in Figure 5 , F-12509a displayed a dose-and time-dependent cytotoxicity to parental HL-60 cells (Figure 5a ), chemoresistant HL-60/Doxo (Figure 5b ) and HL-60/VP16 cells (Figure 5c ) at low micromolar concentrations. The cytotoxic effect observed at 72 h was similar in drug-sensitive and chemoresistant cells. The antiproliferative effect of F-12509a was clearly apoptosis as manifested by the strong nuclear fragmentation observed in treated HL-60/Doxo (Figure 5d ) and HL-60/VP16 cells (data not shown) compared to vehicle-treated control. Executioner caspase-3 and -7 activation as well as proteolysis of PARP were distinctly seen in chemoresistant HL-60/Doxo cells after exposure to F-12509a (Figure 5e ). Notably the endogenous inhibitor of caspase-3 and -7, XIAP, whose pathological overexpression occurs in many cancers, 35 was found cleaved upon treatment with F-12509a (Figure 5e ). In addition, F-12509a was also able to trigger the release of two major proapoptotic proteins from the mitochondria namely cytochrome c, which activates the apoptosome and therefore the caspase cascade, and SMAC/Diablo, the negative regulator of IAPs (Figure 5e ). In agreement with the proposed site of action of SphK1 (this work) and S1P, 11 these findings demonstrate that SphK1 regulation is likely to occur at the premitochondrial level.
S1P counteracts the proapoptotic effect of F-12509a
As SphK1 activity downregulation was observed with F-12509a compound, thus altering the ceramide/S1P balance in favor of ceramide (Figure 4c and d) , we hence asked whether addition of exogenous S1P could restore survival of cells treated with F-12509a. As shown in Figure 5f , S1P was capable of markedly blocking loss of cell viability triggered by F-12509a in both MDR HL-60 cell lines.
Concluding remarks
The MDR phenotype, commonly observed in malignant acute myeloid leukemia cells exposed to anthracyclines or plantbased alkaloids, remains a major obstacle to successful chemotherapy. For that reason, the search for agents that can overcome chemoresistance in leukemia is a worthwhile task. Whatever is the exact mechanism of action of these MDR proteins (decrease of intracellular drug accumulation or attenuation of the consequences of intracellular drug accumulation), the final outcome is a resistance to chemotherapeutic drug-induced apoptosis (reviewed in Sietsma et al. 36 , Pallis et al
. 37 ). The present investigation illustrates for the first time the involvement of SphK1 in chemoresistance of acute myeloid leukemia cells. Moreover, we demonstrate that manipulation of the sphingolipid balance between proapoptotic ceramide and anti-apoptotic S1P is a relevant strategy, explicitly through SphK1 inhibition, placing SphK1 in the limelight as a potential therapeutic target in the treatment of acute myeloid leukemia. SphK1 is a key enzyme in sphingolipid metabolism, because it serves the dual function of modulating ceramide and S1P levels: not only it produces the progrowth, antiapoptotic messenger S1P, but also decreases intracellular levels of the proapoptotic ceramide, counterbalancing its effect. Herein, in accordance with our previous observations on irradiation-induced apoptosis of prostate cancer cells, 18 we show that SphK1 acts a sensor during ceramide-mediated chemotherapy-induced apoptosis of acute myeloid leukemia cells. In cells that are responsive to doxorubicin or etoposide treatment thus undergoing apoptosis, the ceramide/S1P two-pan balance is tipped toward ceramide together with downregulation of SphK1 activity. Conversely, the ceramide /S1P balance remains steady in chemo-resistant variants with no down-regulation of SphK1 activity. The mechanism underlying SphK1 inhibition during apoptosis and its meaning are not known. While this work was in completion, in line with our findings, a downregulation of SphK1 protein in the Molt-4 leukemia cells following treatment with DNA damaging agents in a p53-dependent manner was reported. Nonetheless, one can speculate that ceramide generation is needed for down-regulation of SphK1 activity given that SphK1 inhibition comes about after treatment with C 2 -ceramide, a short-chain homologue of natural ceramide, which is known to be metabolized to form natural long-chain ceramides, when added to the cells. 38 With respect to the meaning of SphK1 inhibition during apoptosis, one can instinctively envision it as a way to ensure that the ceramide produced -in response to stress agents -will not give rise to increased anti-apoptotic S1P. The metabolic conversion of ceramide into S1P may switch cancer cells from an apoptotic state to a cell growth/survival state. As aforesaid, the sphingolipid metabolism can be viewed as a dynamic flow in which increase in ceramide level can lead to augmented S1P level as well, unless SphK1 is inhibited by a mechanism acting hence like a flood barrier. Ceramide generation alone might not be enough to mediate successfully apoptosis without inhibition of prosurvival SphK1.
A strategic role for SphK1 in regulating chemotherapeuticsinduced apoptosis in AML cells is supported by its overexpression that could markedly inhibit cell death induced by doxorubicin, etoposide, and cell-permeable ceramide. These results corroborate previous findings showing that SphK1 overexpression protects from proapoptotic stimuli that provoke generation of endogenous ceramide such as serum withdrawal in NIH 3T3 cells and Jurkat T cells, 7 9 Enhanced SphK1 activity reduces ceramide level by driving ceramide metabolism toward the synthesis of S1P, which thwarts the apoptotic machinery likely at the premitochondrial level via inhibition of cytochrome c release. 11 In agreement, we demonstrate here for the first time that SphK1 overexpression inhibit cytochrome c release induced by chemotherapeutics. Of interest, enforced expression of a dominant-negative form of SphK1 even sensitized to some extent HL-60 cells to doxorubicin-and etoposide-induced apoptosis further establishing that SphK1 is indeed important in the regulation of ceramidemediated apoptosis. In agreement with the recent studies from Obeid and co-workers in MCF7 breast cancer cells 32 and Spiegel et al. in melanoma cells, 10 SphK1 knockdown by specific siRNA could trigger a significant reduction in cell viability of both sensitive and chemoresistant HL-60 cells suggesting that SphK1 was required for cell survival and that attenuation of SphK1 may be important for the execution of cell death.
Strategies to kill tumor cells by increasing their ceramide content or blocking S1P accumulation should have a favorable therapeutic index and circumvent MDR chemo-resistance. 1, 39 Herein, we have established proof-of-concept that both genetic and pharmacologic suppression of SphK1 could restore ceramide generation and apoptosis in MDR chemo-resistant acute myeloid leukemia cells. The F-12509a SphK inhibitor compound simultaneously blocked S1P biosynthesis and caused ceramide accumulation, efficiently accomplishing this goal in one step. At low micromolar amounts, F-12509a clearly triggered apoptosis in HL60 cells regardless of their MDR status through a mitochondria-dependent pathway as release of cytochrome c and SMAC/Diablo followed by the inactivation of XIAP characterized by its cleavage.
Importantly, contrary to the SphK inhibitors used thus far such as dimethyl-, trimethyl-, or dihydro-sphingosine, F-12509a has more attractive features in particular a much higher specificity. 33 Actually, F-12509a does not inhibit other lipid kinases nor protein kinase C 33 in contrast to these sphingosine derivatives. [40] [41] [42] Even though sphingosine derivatives were found equipotent for primary leukemic and drug-resistant leukemia cells, [43] [44] [45] and capable of inhibiting tumor growth in vivo, they did cause strong hemolysis, [46] [47] [48] a drawback that is not seen with F-12509a. This latter indeed is not toxic in mice (Calvet C, Cuvillier O, unpublished observations) making F-12509a a good candidate for further studies in animals.
As MDR proteins expression is among the strongest prognostic factors in acute myologenous leukemia, SphK1 inhibitors such as F-12509a, by mediating the removal of blockers of apoptosis and renewing their sensitivity to cell death regardless of MDR status, hold promise for further clinical development, and may lead to new targeted drugs for our arsenal to fight cancer.
